Pfizer says trials show COVID-19 antiviral pill cuts hospitalisation and death risk by nearly 90 per cent

Pfizer says its experimental antiviral pill for COVID-19 cut rates of hospitalisation and death by nearly 90 per cent in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus.